Monday, August 04, 2025 10:18:50 AM
According to Yahoo Finance, over a Million shares were shorted as of 7/15.
Doubt many of them that are still short will want to be there with the pending
approval, may be fueling todays 'bounce' back.
But also expect the shorts will show up (IF approved) when it peaks post approval
and try to hit it again.
Cause there will be a 'lull' period between approval (IF) and a qtr when sales revenues
are actually gaining ground for them to mess around with it.
Few unknowns to ponder IF approved
-peak price
-will they do a forward split to make more shares available for the institutional players
which would knock the share price down and take away some of the incentive for the shorts
to hit it (lot better shorting at $45 than it is at say $10)
-will the institutionals grab shares and increase their share count. Or will it be like CRMD and
for some unknown reason, the institutionals have NOT been buying shares like it was expected
they would.
To be determined.
Doubt many of them that are still short will want to be there with the pending
approval, may be fueling todays 'bounce' back.
But also expect the shorts will show up (IF approved) when it peaks post approval
and try to hit it again.
Cause there will be a 'lull' period between approval (IF) and a qtr when sales revenues
are actually gaining ground for them to mess around with it.
Few unknowns to ponder IF approved
-peak price
-will they do a forward split to make more shares available for the institutional players
which would knock the share price down and take away some of the incentive for the shorts
to hit it (lot better shorting at $45 than it is at say $10)
-will the institutionals grab shares and increase their share count. Or will it be like CRMD and
for some unknown reason, the institutionals have NOT been buying shares like it was expected
they would.
To be determined.
Recent TNXP News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 11:05:28 AM
- Tonix Pharmaceuticals Announces Presentation of Phase 1 Data and Plans for an Adaptive Phase 2 Field Study of TNX-4800 (anti-Borrelia OspA monoclonal antibody) for the Prevention of Lyme Disease at the 4th Annual Ticks and Tickborne Diseases Symposium at J • GlobeNewswire Inc. • 04/29/2026 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/23/2026 11:11:37 AM
- Tonix Pharmaceuticals Presents Updates on Preclinical Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2026 • GlobeNewswire Inc. • 04/23/2026 11:00:00 AM
- Tonix Pharmaceuticals Announces Publication of Steady-State Pharmacokinetics of TONMYA® After 20 Days of Daily Dosing in the Peer-Reviewed Journal, Clinical Pharmacology in Drug Development • GlobeNewswire Inc. • 04/15/2026 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/31/2026 11:05:34 AM
- Tonix Pharmaceuticals Announces Presentation of Phase 1 Data and Outlines Planned Adaptive Phase 2 Field Study of TNX-4800 for the Prevention of Lyme Disease, at the World Vaccine Congress Washington 2026 • GlobeNewswire Inc. • 03/31/2026 11:00:00 AM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/30/2026 12:00:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/26/2026 11:00:28 AM
- Tonix Pharmaceuticals Announces First Participant Dosed in Phase 1 Investigator-Initiated Pharmacodynamic Study of TNX-1900 (Intranasal Potentiated Oxytocin) to Assess Potential for Treating Migraine and Craniofacial Pain • GlobeNewswire Inc. • 03/26/2026 11:00:00 AM
- Tonix Pharmaceuticals Announces Presentations at World Vaccine Congress Washington 2026 • GlobeNewswire Inc. • 03/23/2026 08:32:42 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/20/2026 09:12:47 PM
- Tonix Pharmaceuticals to Present at BIO-Europe Spring 2026 • GlobeNewswire Inc. • 03/18/2026 08:58:49 PM
- Tonix Pharmaceuticals Announces Oral Presentation and Two Poster Presentations on Preclinical Immuno-oncology Portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026 • GlobeNewswire Inc. • 03/17/2026 08:35:00 PM
- Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing • GlobeNewswire Inc. • 03/13/2026 12:35:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/13/2026 10:01:04 AM
- Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights • GlobeNewswire Inc. • 03/12/2026 09:30:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/12/2026 09:29:52 PM
- Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th • GlobeNewswire Inc. • 03/10/2026 02:21:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/10/2026 12:05:34 PM
- Tonix Pharmaceuticals Presented Post Hoc Analyses of Phase 3 Data on TONMYATM at the 8th International Congress on Controversies in Fibromyalgia • GlobeNewswire Inc. • 03/10/2026 12:00:00 PM
- Tonix Pharmaceuticals Presented Data on TONMYATM in Treating Patients with Fibromyalgia at the 2026 AAPM PainConnect Annual Meeting • GlobeNewswire Inc. • 03/09/2026 08:30:00 PM
- Tonix Pharmaceuticals Announces Publication of Clinical Pharmacokinetic Studies of TONMYA™ and Prototype Formulations in the Journal Clinical Pharmacology in Drug Development • GlobeNewswire Inc. • 03/05/2026 09:15:00 PM
- Tonix Pharmaceuticals to Present Poster on Tonmya™ at the 2026 American Academy of Pain Medicine PainConnect Annual Meeting • GlobeNewswire Inc. • 03/03/2026 09:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/03/2026 11:05:34 AM
